Amgen-AstraZeneca’s Tezspire nets another Phase III inflammatory disease win

If approved in EoE, Tezspire will notch another indication onto its belt – adding to its legacy defined by approvals in asthma and CRSwNP. If approved in EoE, Tezspire will notch another indication onto its belt – adding to its legacy defined by approvals in asthma and CRSwNP. Tezspire has already secured approval in severe asthma and CRSwNP. Credit: Kmpzzz / Shutterstock.com. Amgen and AstraZeneca’s co-developed blockbuster therapy Tezspire (tezepelumab) scored a Phase III win in a third epithelial-driven inflammatory disease – potentially paving the way for the drug to secure a new addition to its label. In the CROSSING…

Source: Clinical Trials Arena